What's Trending

Our CMO Dr. Andrew Hertler offers insights for minimizing patients' risk of COVID-19 when their cancer therapies cannot be delayed.

Increasing use of real-world evidence is one of the most exciting trends in pathway development, our CMO tells Journal of Clinical Pathways.

Medscape delves into our work with a community oncology practice to implement high-value clinical pathways and engage providers

Dr. Jeffery Ward, an Oncologist / Hematologist with Swedish Cancer Institute, discusses the initial measures to protect patients, planning for the return of deferred care, and impact of COVID-19.

The pandemic has forced difficult trade-offs between cancer treatment and infection prevention. We also need to be willing to make hard decisions around value, our CMO writes.

Cancer Care Specialists of Illinois reduced drug spend by 13.5% compared to peer practices by deploying our care pathway and physician collaboration protocols

Watch this on-demand webinar to explore the future of cancer care in a post COVID-19 world.

Our chief medical officer, Dr. Andrew Hertler, speaks with Journal of Clinical Pathways about our approach to high-value cancer care.

Caring for a population that is highly vulnerable to COVID-19, oncology practices have had to rapidly adapt for the pandemic. Listen to key takeaways from how oncology practices are responding.

A compilation of infection prevention resources, regulatory updates and guidance for managing high-risk populations in this pandemic.

Prior authorization is a major source of frustration for providers and patients. Our CMO Dr. Andrew Hertler explains how a value-based approach can change that.

As more cancers are treated like chronic conditions, financial toxicity has become a greater problem, our CMO Dr. Andrew Hertler tells Next Avenue.

Navigating the CMS Oncology Care Model can be complicated. Listen to oncologist Dr. Wade describe his OCM experiences and how a partnership with New Century Health positioned his practice for success.

As the pace of treatment innovation threatens the financial health of both patients and oncology practices, it’s time to redefine reimbursement models to care for both financial and physical outcomes.

New Century Health’s clinical pathways are rigorously developed and maintained by company clinicians under the oversight of an independent Scientific Advisory Board. Take a glimpse inside the board.

Our CMO Dr. Andrew Hertler is quoted extensively in this Managed Healthcare Executive roundup of strategies for driving value in cancer care.

Oncology drug spending in the U.S. is on an unsustainable trajectory. Explore four paths to curb costs without compromising care.

Our CMO Dr. Andrew Hertler outlines value-based payment strategies and tools to help oncologists improve care across the patient journey.

Learn how CMS aims to increase risk, cash flow and predictability for practices while reducing administrative burdens, through its next model for value-based oncology care.

As cancer drug prices soar and innovation continues at a dizzying pace, Medicaid plans need a new set of tools to rein in spending and ensure high quality care.

How do you deliver individualized cancer care from both a scientific and human perspective? Read Managed Care Executive for our CMO Dr. Andrew Hertler's thoughts.